Plain-English translation of NCT05488522 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new combination approach for advanced liver cancer that cannot be treated with surgery. Researchers are combining a focused radiation therapy technique called SBRT with two medications: atezolizumab and bevacizumab. The goal is to see if these three treatments work together to help fight the cancer more effectively.
Advanced liver cancer is difficult to treat, especially when surgery is not possible. Doctors want to find out whether combining radiation with this medication approach might offer patients a better option by helping the immune system fight cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive several rounds of focused radiation therapy to your liver, given alongside two medications delivered through infusion or injection. The trial uses a "rolling enrollment" design, which means researchers will carefully monitor your response and any side effects as they gradually adjust treatment doses to find the safest, most effective level. You'll have regular follow-up visits to check how you're responding and to monitor for any side effects.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
United States
Safety & dosing
Sponsor
Abramson Cancer Center at Penn Medicine
Enrollment target
~18 participants
Started
September 2022
Primary completion
December 2026
Age range
18 Years – 99 Years
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Edgar Ben-Josef, MD
Abramson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.